BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 26471512)

  • 1. Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study.
    Creemers-Schild D; Kroon FP; Kuijper EJ; de Boer MG
    Infection; 2016 Jun; 44(3):291-9. PubMed ID: 26471512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study.
    Ohmura SI; Naniwa T; Tamechika SY; Miyamoto T; Shichi D; Kazawa N; Iwagaitsu S; Maeda S; Wada JI; Niimi A
    J Infect Chemother; 2019 Apr; 25(4):253-261. PubMed ID: 30642768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection.
    Kosaka M; Ushiki A; Ikuyama Y; Hirai K; Matsuo A; Hachiya T; Hanaoka M
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
    Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
    BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
    Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
    Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
    Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
    Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Dose vsĀ Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia inĀ Patients Not Infected With HIV: A Multicenter, Retrospective Observational Cohort Study.
    Nagai T; Matsui H; Fujioka H; Homma Y; Otsuki A; Ito H; Ohmura S; Miyamoto T; Shichi D; Tomohisa W; Otsuka Y; Nakashima K
    Chest; 2024 Jan; 165(1):58-67. PubMed ID: 37574166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study.
    Yamashita K; Shimomura Y; Ikesue H; Muroi N; Yoshimoto A; Hashida T
    BMC Infect Dis; 2021 Jul; 21(1):664. PubMed ID: 34238239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: A single-center retrospective observational cohort study.
    Nakashima K; Aoshima M; Nakashita T; Hara M; Otsuki A; Noma S; Misawa M; Otsuka Y; Motojima S
    J Microbiol Immunol Infect; 2018 Dec; 51(6):810-820. PubMed ID: 28779879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Retrospective investigation of side effects and prognoses of moderate-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia that developed in patients with autoimmune diseases].
    Shibata T; Tonooka K; Tsuchida K; Mitomi H; Shibata T; Katsuyama N
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):213-8. PubMed ID: 27320937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases.
    Takenaka K; Komiya Y; Ota M; Yamazaki H; Nagasaka K
    Mod Rheumatol; 2013 Jul; 23(4):752-8. PubMed ID: 22907597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of
    Harada T; Kato R; Sueda Y; Funaki Y; Takata M; Okazaki R; Hasegawa Y; Yamasaki A
    Mod Rheumatol; 2021 May; 31(3):629-635. PubMed ID: 32820678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
    Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
    J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients.
    Thomas M; Rupali P; Woodhouse A; Ellis-Pegler R
    Scand J Infect Dis; 2009; 41(11-12):862-8. PubMed ID: 19922070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial.
    Klein NC; Duncanson FP; Lenox TH; Forszpaniak C; Sherer CB; Quentzel H; Nunez M; Suarez M; Kawwaff O; Pitta-Alvarez A
    AIDS; 1992 Mar; 6(3):301-5. PubMed ID: 1567574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.
    Carr A; Tindall B; Penny R; Cooper DA
    AIDS; 1992 Feb; 6(2):165-71. PubMed ID: 1558714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS.
    Chang HM; Tsai HC; Lee SS; Kunin C; Lin PC; Wann SR; Chen YS
    J Chin Med Assoc; 2016 Jun; 79(6):314-9. PubMed ID: 27025225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
    Wordell CJ; Hauptman SP
    Clin Pharm; 1988 Jul; 7(7):514-27. PubMed ID: 3138063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study.
    Park SY; Jung JH; Kwon H; Shin S; Kim YH; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
    Transpl Infect Dis; 2020 Apr; 22(2):e13245. PubMed ID: 31943590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.